Since inhibitors of AKT/mTOR represent potential agents in human cancers, the newly identified PRMT4/AKT/mTOR axis may serve as both a prognostic factor and therapeutic target in HCC. The gene discussed is CARM1; the disease is hepatocellular carcinoma.